FindTrial
Sign In

Efficacy and safety of combined therapy of dry eye for treatment of ocular graft-versus-host disease

Efficacy and safety of combined therapy of dry eye for treatment of ocular graft-versus-host disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000038171
Enrollment
Unknown
Registered
2020-09-12
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ocular graft-versus-host disease

Interventions

Treatment Group:dry eye comprehensive threpy (including Lipiflow,etc.)

Sponsors

Zhongshan Ophthalmic Center, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed as chronic ocular graft-versus-host disease. 2. Aged 18 to 80 year, male or female. 3. Meet the diagnostic criteria of dry eye.

Exclusion criteria

Exclusion criteria: 1. Patients with refractory or secondary systemic infection which require hematologic or other medical treatment. 2. Patients with contraindications for any item of dry eye comprehensive threpy.

Design outcomes

Primary

MeasureTime frame
Assessment of Meibomian Gland;OCULUS Keratograph 5M;Slit-lamp Examination;Confocal Microscopy;Lipiview;Visual Acuity;dry eye symptom;—

Countries

China

Contacts

Public ContactLiang Lingyi

Zhongshan Ophthalmic Center, Sun Yat-Sen University

lianglingyi@qq.com+86 13829738319

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026